 MELBOURNE, Australia , June 27, 2022 PRNewswire -- Incannex Healthcare Limited NASDAQ: IXHL ASX: IHL, Incannex or the Company a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that Dr. Paul Liknaitzky, Head of Clinical Psychedelic Research at Monash University and Chief Principal Investigator for Incannexs psilocybin-assisted psychotherapy, will present an overview of progress achieved in Incannexs psychedelic medicine program at the H.C. Wainwright First Annual Mental Health Conference, taking place June 27, 2022. 